Detalles de la búsqueda
1.
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer.
Ann Oncol
; 35(3): 285-292, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38061427
2.
Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial.
Future Oncol
; 17(14): 1699-1707, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33554636
3.
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer.
Ann Oncol
; 31(7): 930-941, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32289380
4.
Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents.
Ann Oncol
; 34(6): 557-563, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36958590
5.
Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ann Oncol
; 34(3): 228-246, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36563965
6.
Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
Ann Oncol
; 29(11): 2200-2207, 2018 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30202945
7.
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
Ann Oncol
; 29(5): 1249-1257, 2018 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29788164
8.
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.
Ann Oncol
; 29(8): 1658-1686, 2018 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30113631
9.
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.
Ann Oncol
; 28(11): 2741-2746, 2017 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29059273
10.
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Ann Oncol
; 28(1): 90-95, 2017 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28039155
11.
Circulating tumor DNA in patients with metastatic prostate cancer treated with abiraterone acetate.
Ann Oncol
; 32(6): 694-695, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33839261
12.
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.
Ann Oncol
; 27(4): 699-705, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26609008
13.
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.
Ann Oncol
; 27(3): 454-60, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26685010
14.
Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.
BMC Cancer
; 16: 168, 2016 Feb 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-26923772
15.
Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
Ann Oncol
; 26(8): 1660-7, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26002607
16.
Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial.
Ann Oncol
; 26(1): 179-185, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25361992
17.
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol
; 31(9): 1119-1134, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32593798
18.
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.
Ann Oncol
; 26(2): 368-74, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25425475
19.
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
Ann Oncol
; 26(8): 1589-604, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26041764
20.
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial.
Ann Oncol
; 25(2): 429-34, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24478320